Atrasentan

AssetAlso called atrasentan hydrochloride, CHK-01, ABT-627, Vanrafia

Blocks endothelin A receptor signaling involved in tumor growth and survival.

Stage
Approved
Modality
Small molecule
Target
EDNRA
18
Indications
18
Trials
4
Developers

Approved by the FDA on Apr 2, 2025 (NDA219208). FDA

Indications

18

15 more

In the full profile

  • Target and mechanism1
  • Owner and partners4
  • Trials18
  • Evidence for its targets2
  • Competitors12
  • Signals12

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets